http://www.acc.org/Feed?clinicalTopicID=677b3288-77e4-47f8-8697-3e2ce6a4dd87 Clinical Topic Feed: Anticoagulation Management en /Latest-in-Cardiology/Articles/2026/05/12/15/21/eagles-eye-view-13may2026 In this week’s View, Dr. Eagle examines the role of rhythm control in improving moderate-to-severe and severe secondary tricuspid valve regurgitation. 1778679000000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/05/04/11/24/Continuing-vs-Switching-DOAC-Therapy In patients with atrial fibrillation (AFib) experiencing a breakthrough ischemic stroke while on a direct oral anticoagulant (DOAC) regimen, switching to a different DOAC was noninferior to continuing the same DOAC, according to a study published April 28 in JAMA Network Open. 1778074320000 Articles and Stories /Latest-in-Cardiology/Articles/2022/01/01/01/01/ACC-Featured-Jobs Ready to explore a new professional opportunity? Browse the list below of featured jobs and take the next step in your career! 1777629480000 Articles and Stories /Latest-in-Cardiology/Articles/2026/04/29/14/55/eagles-eye-view-29apr2026 In this week’s View, Dr. Eagle looks at endovascular therapy for post-thrombotic syndrome and how it reduces severity and improves quality of life. 1777474620000 Articles and Stories /Latest-in-Cardiology/Articles/2026/04/21/15/23/CHAMPION-AF The CHAMPION-AF trial randomized 3,000 patients with nonvalvular atrial fibrillation (AFib) (mean age, 72 years; mean CHA2DS2-VASc score, 3.5; mean HAS-BLED score, 1.3) who were suitable for long-term oral anticoagulation to either left atrial appendage closure (LAAC) (Watchman Flx, Boston Scientific) or non–vitamin K antagonist oral anticoagulants (NOACs). 1776939000000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/04/22/11/23/OCEANIC-STROKE Asundexian lowered the risk of ischemic stroke and major cardiovascular events, without increasing the risk of major bleeding, in patients with noncardioembolic stroke or high-risk transient ischemic attack (TIA) taking antiplatelet therapy, according to results from the phase 3, double-blind OCEANIC-STROKE trial, published April 15 in NEJM. 1776865440000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/04/21/16/07/Current-Evidence-and-Strategies The influences of sex hormone therapy – for contraception, treatment of heavy menstrual bleeding, hormone-replacement therapy, gender-affirming care therapy, etc. – on venous thrombotic and cardiovascular risk was explored in a Review Article published April 15 in NEJM. 1776793020000 Articles and Stories /Latest-in-Cardiology/Articles/2026/04/01/15/58/cardiacast_01apr2026 In this episode, Gregory Piazza, MD, FACC, Elvira Grandone, MD, PhD, and Abbey R. Kruper, PsyD, ABPP walk through the clinical and emotional challenges of the link between thrombosis and fertility. 1775232180000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/25/21/27/sat-930am-championaf-acc-2026 Device-based left atrial appendage (LAA) closure was comparable to non-vitamin K antagonist oral anticoagulant (NOAC) therapy in reducing the combined rate of death from cardiovascular causes, stroke, or systemic embolism at three years in patients with atrial fibrillation (AFib) who were candidates for anticoagulation, based on findings from the CHAMPION-AF trial presented at ACC.26 and simultaneously published in NEJM. In addition, LAA closure was superior to long-term NOAC therapy for pre-specified non–procedure-related bleeding over the same time period. 1774708380000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/25/21/27/sat-930am-hipeitho-acc-2026 In patients with acute, intermediate-risk pulmonary embolism (PE), ultrasound-facilitated, catheter-directed fibrinolysis plus anticoagulation led to a lower risk of PE-related death, cardiopulmonary decompensation or collapse, or recurrence of PE compared with anticoagulation alone. These findings from the HI-PEITHO trial were presented at ACC.26 in New Orleans and simultaneously published in NEJM. 1774708320000 Articles and Stories